Alnylam Pharmaceuticals Inc., of Cambridge, Mass., added Barry Greene as chief operating officer.

Angiogenix Inc., of New York, hired Patricia D'Amore to serve as a consultant and a member of the company's scientific advisory board.

AtheroGenics Inc., of Atlanta, promoted David Edwards to vice president of early development.

Atrix Laboratories Inc., of Fort Collins, Colo., named Brian Richmond interim chief financial officer.

Barrier Therapeutics Inc., of Princeton, N.J., appointed Albert Bristow general counsel and added Peter Ernster to its board.

Chiron Corp., of Emeryville, Calif., named David Smith chief financial officer.

CytoGenix Inc., of Houston, added John Rossi to its board.

eXegenics Inc., of Dallas, appointed Gordon Martin to its board.

FemmePharma Inc., of Wayne, Pa., added Carolyn d'Arville and Lisa Rarick to its scientific advisory board.

Flamel Technologies SA, of Lyon, France, added Raul Cezan, William Dearstyne and Michel Grecco to its board.

Genetronics Biomedical Corp., of San Diego, appointed Gene Larson to its board.

Graffinity Pharmaceuticals AG, of Heidelberg, Germany, named Mathias Woker vice president, business development USA.

Health Discovery Corp., of Waco, Texas, named Bernard Scholkopf to its scientific advisory board.

Lexicon Genetics Inc., of The Woodlands, Texas, elected Alan Nies to its board.

Peninsula Pharmaceuticals Inc., of Alameda, Calif., promoted Matthew Wikler to executive vice president and chief medical officer and Debra Odink to vice president, pharmaceutical chemistry and product development.

Peptimmune Inc., of Cambridge, Mass., added Thomas Mathers as president.

Photogen Technologies Inc., of San Diego, added Richard Dean to its board.

Sagres Discovery, of Davis, Calif., added Raymond Stevens, Ali Fattaey, Frank McCormick, Mark Pegram, Wilbur Leopold and Tony Hunter to its scientific advisory board.

Samaritan Pharmaceuticals Inc., of Las Vegas, and Samaritan Research Labs at Georgetown University said Thomas Long joined Samaritan Pharmaceutical's advisory board.

Seattle Genetics Inc., of Bothell, Wash., named Antonio Grillo-Lopez and Michael Caligiuri to its scientific advisory board. It also added Michael McDonald as chief medical officer.

Sirna Therapeutics Inc., of Boulder, Colo., appointed Ivan Richards senior director, pharmacology.

SomaLogic Inc., of Boulder, Colo., appointed Charles Lillis to its board.

SuperGen Inc., of Dublin, Calif., promoted Edward Jacobs to chief operating officer.

Terra Nostra Technology Ltd., of Montreal, appointed Kebir Ratnani to its board.

Varian Inc., of Palo Alto, Calif., appointed Martin O'Donoghue vice president, scientific instruments.

Viragen Inc., of Plantation, Fla., added Per-Erik Persson to its board.

Xechem International Inc., of New Brunswick, N.J., appointed William Pursley to its board as vice chairman.